Woodley Equipment has expanded its support team with the appointment of Greg Woloszczuk as the new Wet Chemistry Product Support Specialist.
Greg joins Woodley from the veterinary industry where he worked for 5 ½ years as a Service Manager. He will focus on all areas of customer service, pre and post sales, along with organising servicing, repairs and maintenance of the Woodley wet chemistry analysers.
Royal Canin is offering Dyson Animal handheld bagless vacuum cleaners (normally retailing at £130) with orders of over £500 at Congress this year.
The Royal Canin Veterinary range will be on display, including the latest additions for cats, Renal Special Dry and Renal with Tuna.
Delegates can also find out more about Royal Canin’s programme of on-site in-practice staff training on nutrition, Pet Health Counsellor courses and extensive support material for veterinary nurses, receptionist courses, display material for the waiting room, and a helpline to ensure that vets and their teams have quick access to the most up to date information.
Everyone who drops in on Royal Canin will also be able to enter a free draw to win a flight in a hot air balloon.
Two recently published studies have demonstrated that the canine anti-emetic Cerenia® (maropitant - Pfizer) which was launched last year also relieves car sickness in dogs.
In a pilot study, 17 dogs were given either Cerenia or placebo one hour before being taken on a car journey. After a washout period of 10-14 days, each dog was crossed over to the other treatment and once again taken on a journey to assess travel sickness. The results showed that likelihood of vomiting was reduced by 70% when the dogs were given Cerenia compared to placebo – but due to the small number of dogs enrolled the results did not reach statistical significance.
The same research group also carried out a large, multicentre, blinded and placebo controlled study of Cerenia in preventing vomiting in 213 dogs known to be prone to travel sickness. They were given a single oral dose of Cerenia or placebo one hour before a car journey. The results showed that Cerenia was associated with a reduction in vomiting of 79% compared to placebo (p<0.0001).
The dosage of Cerenia used in both studies was 8mg/kg dose for the prevention of motion sickness–higher than the 2mg/kg dose that is routinely used to treat general emesis, administered at least one hour before the journey. According to the researchers’ report in the Veterinary Record, the need for a higher dose is linked to the specific neural (central) pathway of emetic stimulation that is involved in motion sickness. Cerenia acts primarily at NK1 receptors in the emetic centre and thus has the ability to block vomiting due to vestibular stimuli.
According to Pfizer, a single oral dose lasts for at least 12 hours, so pets can be dosed the night before an early start. For motion sickness prevention, Cerenia is licensed for up to 2 days’ consecutive use, so owners can use it for a return journey the next day if need be.
Pfizer also says that market research suggests almost one in five dogs suffers from travel sickness, which is not only inconvenient but does also stop some owners from travelling with their pet. In the past, owners have had to rely on OTC (over the counter) remedies or medicines developed for use in humans to prevent travel sickness. Many of these are ineffective or have unwanted effects such as sedation or extrapyramidial effects in dogs. Cerenia is the first anti-emetic to be developed specifically for use in dogs and was launched in April 2007– higher dose tablets aimed specifically for the prevention of travel sickness are expected to be made available early this year.
Vetoquinol, makers of Sedalin (acepromazine), has published a free clipping guide for horse owners.
The company says the launch of the guide has been timed to coincide with the horse clipping season, when owners may be considering sedating horses to make things safer for themselves and their horses.
The guide refers owners to their veterinary surgeon for professional advice if sedation is appropriate.
The company has also produced promotional practice posters: ' Less Stress more Success'
For your poster and accompanying guides, contact your Vetoquinol Territory Manager or Teleservices directly on 01280 825424. You may also wish to put a link to a downloadable version of the guide on your practice website: http://www.vetoquinol.co.uk/clippingguide.pdf
Hill's has launched VetEssentials NeuteredCat, a low fat diet for the 90% of UK cats that are estimated to have been neutered.
According to the company, neutered cats are over three times more likely to become overweight and/or suffer from urinary problems.
Hill's says that the low fat formulation of NeuteredCat keeps energy density low, and that its unique Weight Management Formula optimises fat metabolism, whilst preserving lean muscle through supplementation with L-carnitine and L-lysine. The company also claims that NeuteredCat helps to maintain urinary health with levels of minerals carefully controlled to generate a target urine pH of 6.2-6.4.
There are a range of educational and marketing resources to support the new product, available from the company's territory managers.
VetEssentials NeuteredCat will replace any orders made for Science Plan Neutered cat over the coming months.
Royal Canin is launching a new packaging format for its range of feline wet diets.
The company says the launch comes in response to research showing that more than three-quarters of pet owners (76%1) feed their cats wet food and almost half of wet cat products sold are in a canned format (48%2).
The current alutray packaging will be replaced by 195g cans, which Royal Canin says are easier to use and store, and which clients believe to be better value for money than other packaging formats.
The new cans will contain the same recipes as before, with the same balance of nutrients in each wet diet. They will consist of a loaf or mousse, providing a complementary texture to the chunks in gravy found in the equivalent pouched diets.
Royal Canin is also highlighting the benefits for veterinary practices: The cans are designed to provide greater clarity of display and on-shelf presence. They are also easier to stack for storage, and they meet an established demand.
Ian Williams, one of Royal Canin's small animal vets, said: "We believe the new packaging is an improvement on our established and popular range of wet Veterinary Diets for cats. The range is extensive which allows owners to follow a vet's nutritional recommendations without changing their pets' feeding habits, an excellent way to increase compliance."
The new canned format will be phased in as stocks are replenished, with the following cans being added to the Royal Canin range of wet feline foods: a new Renal and Urinary S/O can, joining the existing Recovery can within the range of Veterinary Diets; and a new Paediatric Weaning can within the Veterinary Care Nutrition range.
For more information about Royal Canin and the diets, visit www.royalcanin.co.uk.
References
Vétoquinol has launched Flexadin, a new range of joint support products for cats and dogs with osteoarthritis (OA)
Robert Simpson, Flexadin Product Manager said: "This new range is made up of two products: Flexadin Plus and Flexadin Advanced, both are dietetic complementary feeds which are members of a small group of joint support products which contain Omega-3 fatty acids and Vitamin E. These ingredients are proven to aid the support of the metabolism of joints in the case of OA. Although many different joint support aids are available, not all of them contain these extra ingredients."
Vétoquinol says that in addition to Omega-3 fatty acids and Vitamin E, Flexadin Plus contains the traditional ingredients: glucosamine, chondroitin and devil's claw. Flexadin Advanced contains the novel ingredient, UCII - a type of undenatured type II collagen which has been manufactured using a patented process.
Flexadin Plus comes in two formulations, the first is specifically designed for cats/small dogs and the other is for medium/large dogs. Flexadin Advanced is specifically for dogs.
Robert added: "Flexadin Advanced has a specific property which means that the administration rate is only one chew per day whatever the weight of the dog. This has an important impact on the price per day for medium and large dogs which may require more than one tablet of traditional joint support products. This property also makes Flexadin Advanced a convenient option for owners. In addition to this benefit, UCII is becoming more and more popular due to the results of scientific studies in dogs, horses and even humans.
"We are all very excited about the advances this range can bring to veterinary practices."
Both Flexadin Plus and Advanced are presented as palatable, shaped, soft chews which come in zip-lock packs to keep the soft chews fresh and tasty. Flexadin Plus comes in packs of 90 chews whilst Flexadin Advanced comes in packs of 30 chews.
For further information about Flexadin, contact Vétoquinol on: 01280 825424.
Normally only accessible by ISFM members, the channel has been opened up as a free resource to help vets keep on top of CPD and includes over 40 webinars presented by internationally recognised veterinary specialists.
Topics include: anaesthesia and analgesia, behaviour, emergency and critical care, feline medicine and neurology. Each webinar is worth 1 hour of CPD and you get a certificate.
The channel includes a new webinar: ‘COVID-19 – helping cats cope’ which looks at how you can advise owners to help their cats deal with changes at home.
ISFM’s Feline Medicine Consultant, Sam Taylor said: "ISFM is committed to educating veterinary professionals on all things feline, so we are delighted to be able to bring some of our normally member-only benefits to a wider audience during this challenging time."
To register for the ISFM webinar channel, visit: https://icatcare.org/event/isfm-vet-webinars/
The awards, which which celebrate initiatives that advance the quality of veterinary care and demonstrate a commitment to using an evidence-based approach, will be open for applications until 13th January 2023.
The two new award categories are Antimicrobial Stewardship and Canine Cruciate Outcomes.
The Canine Cruciate Outcome Awards are to recognise and celebrate individuals and teams who are using Quality Improvement initiatives alongside RCVS Knowledge’s Canine Cruciate Registry (CCR) to monitor and improve their canine cruciate surgery outcomes.
Applications are invited by surgeons and teams who are using the CCR.
The Antimicrobial Stewardship Awards, which are divided into farm animal, equine, and companion animal categories, aim to showcase practical examples where individuals and teams are improving responsible antimicrobial prescribing.
In addition, the charity is looking for entries for its existing awards for students and those who have implemented Quality Improvement (QI) techniques.
The Veterinary Evidence Student Awards enables students from around the world to enhance their academic and research skills by writing a Knowledge Summary and submitting it for publication to Veterinary Evidence, RCVS Knowledge's open access, peer-reviewed journal.
The Quality Improvement Awards showcase the implementation of Quality Improvement techniques which drive improvement within the professions.
www.rcvsknowledge.org/awards
BlueSky says that conventional treatment for equine sarcoids, which are induced by tumour antigens E6 and E7 of the bovine papillomavirus, have only limited effect and typically result in the recurrence of the tumours.
However, research published by the company in PLoSONE1 showed that sarcoids treated with delNS/E6E7 were completely and permanently eliminated.
For the study, 29 horses were treated with different regimes involving direct injection into the tumours over three years.
Visible and very significant regression of the sarcoids was achieved in 20 of the treated horses, and 100% regression of the sarcoids in 10 equine patients.
Thomas Muster, CEO of BlueSky Immunotherapies said: "The complete elimination of very aggressive and difficult-to-cure equine sarcoids is yet another important proof of the potential offered by our delNS platform."
In addition, the systemic delNS-mediated immune stimulation eliminated non-injected sarcoids and the papillomavirus that caused the sarcoids.
Thomas added: "We are therefore confident that we will also be able to successfully heal and/or eliminate the cervical tumours of the women enrolled in the clinical trials currently under way."
Reference
For the research, Which? conducted an online poll of 1,009 pet owners who had had an issue with their vet in the past two years.
It also conducted qualitative interviews with 14 owners who had complained.
The most common reasons for complaint were:
Of the 1009 pet owners who had experienced some kind of problem with their vet, 57% did NOT make a complaint, 33% because they did not want to fall out with their vet.
Pet owners who wish to complain about veterinary services have three options: to complain directly to their practice, to use the voluntary Vet Client Mediation Service (VCMS), or to raise a 'concern' with the RCVS.
The Which? report found that of those who did complain to their practice, 35% were not happy with the outcome and 31% with the way it was handled.
Which? found that although the VCMS reported a high resolution rate of 84% in 2022-23, its interviewees had found it a bit hit or miss.
Finally, Which? found the process of complaining to the regulator flawed by the fact that the threshold for the College to progress a 'concern' is set so high, because College has no jurisdiction at a practice level, and because it has no sanctions to use in enforcing consumer law.
The report recommends that:
Full report: https://www.which.co.uk/policy-and-insight/article/complaints-and-redress-in-veterinary-services-a5z611X9tZzf
CommentI loved the regal response from the RCVS to The Guardian about the case studies in the Which? report: “the facts presented in the case studies do not completely align with those reported to us”.
That aside, surely the big issue here is not so much that consumers have little way to complain effectively.
That is important, of course, but isn't it more important to consider what they are complaining about, which in the main is MONEY.
Driven by the advances in veterinary medicine, the innate desire of vets to provide the best possible care, anthropomorphising pet owners saying they want 'the best' for their fur baby (without necessarily having the wherewithal), corporatisation and society's changing expectations about working conditions, prices have been going up at a rate far outstripping inflation.
Increasing prices have of course been accompanied by an increase the standards of care and the range of clinical equipment.
But the question everyone must ask is at what point the cost of veterinary care for a dog outstrips the benefits of owning one?
These complaints are the canary in the coalmine.
Conducted as a multicentric international study involving board-certified veterinary dermatologists, the trial included 35 dogs with CIF in at least two paws.
Each dog acted as its own control, and was treated with systemic antibiotics, with one paw being treated with FLE and the other paw without.
Paws were allocated based on a coin toss, and the study was single blinded: the principal investigator was responsible for the assessment of lesions, and the co-investigator was responsible for administration of FLE treatment.
The dogs were assessed over an 8-week period with check-ups every 14 days.
At every check-up the paws treated with FLE showed a greater improvement than paws without FLE treatment.
The lesions were assessed and scored with the global lesion score, the pruritic visual analogue scale, a cytological scoring, and photographic documentation.
The results of the study demonstrated that FLE combined with systemic antibiotics significantly reduced the time to clinical resolution compared to antibiotics alone.
By week four, 50% of paws in the FLE group had reached clinical resolution compared to 17% in the control group.
By week eight, 88% of paws in the FLE group had healed compared to 54% in the control group.
Dr Anja Lange, DVM, Department of Dermatology, AniCura Kleintierspezialisten Augsburg GmbH, Augsburg, Germany, said: “Canine interdigital furunculosis is a challenging condition to treat that can be prolonged and frustrating.
"Having FLE as an additional management tool is very exciting, not least because it speeds up time to healing, but it also requires us to use less antibiotics.
"The use of FLE was well accepted by all of the dog owners from the study and the dogs themselves tolerated it well, showing it can be a very useful adjunct to cases in clinical practice.”
Zoë Coker, a co-founder of VETbytes alongside Bronwen Eastwood, said: "This new feature will allow users to access real-time updates to the app so they can be assured they are following the most up-to-date clinical guidance."
The app, which was launched in partnership with the BSAVA earlier this year, covers more than 100 topics and includes other features such as drug (and CRI) calculators, a quick reference section and links to hundreds of source abstracts, as well as CPD accreditation for reflective learning.
It is available at a discount to BSAVA members and free to veterinary students.
BSAVA President Professor Ian Ramsey said: “The latest addition to the app advances our joint goal with VETbytes, to provide the latest practical, accessible, evidence-based resources for the small animal veterinary community.”
To view the ‘latest updates’ feed: https://vetbytes.co.uk/latest-updates.
For more information, visit: www.vetbytes.co.uk.
The RCVS has announced a total of £1 million funding to address mental health and wellbeing within the veterinary profession over the next five years.
The RCVS Operational Board has agreed £100K of funding for the first year of the Mind Matters initiative, with a view to a similar amount per year for the subsequent four years.
Additionally, the College says it intends to contribute approximately £500K over the next five years to the Veterinary Surgeons' Health Support Programme (VSHSP). This is a continuation of previous funding, effectively doubling the College's contribution. The VSHSP, independently run by the Veterinary Benevolent Fund, offers a confidential service that aims to combat problems with alcohol, drugs, eating disorders and other addictive and mental health issues. Neil Smith, Mind Matters' Chair said: "I am delighted that we have £500K of new funding over the next five years to dedicate to improving the mental health and wellbeing of the veterinary team, together with the increase to our support for the VSHSP. It shows the College's commitment in this vital area, and is a substantial amount that will really help change lives."
The funding will be reviewed annually as part of the RCVS budgeting process.
Mind Matters activities will fall into five streams:
Mind Matters is supported by a taskforce comprising the Veterinary Benevolent Fund, the British Veterinary Association, the British Veterinary Nursing Association, the Veterinary Practice Management Association, the Veterinary Schools Council, the Veterinary Defence Society, the Society of Practising Veterinary Surgeons and the Association of Veterinary Students.
The session will be conducted in the style of the BBC Radio 4 Moral Maze discussion programme, with panelists and witnesses arguing for and against the viewpoint corporatisation is inevitable and will benefit vets and their clients.
Moderated by Madeleine Campbell, Keith Chandler and Karl Holliman will argue for corporatisation and Andrew Harrison and Tim Greet will be against. They will call upon a series of 'witnesses' for detailed questioning before the topic is more broadly debated.
CVS, the UK’s biggest veterinary group now owns more than 410 veterinary practices, of which over 30 are specifically equine or mixed practices.
The latest equine acquisitions include Bell Equine, a one-site Equine Referral Hospital in Kent, in January 2017 and Severn Edge Veterinary Group, a mixed practice with 12 sites in Shropshire, including a six-vet dedicated equine practice, in April 2017.
One line of argument says that the commercial and business advantages of a corporate, together with their scale and diversity, can give veterinary surgeons greater potential for a more flexible career path and advancement within the industry, and a more sustainable working career in equine practice.
On the flip side, there's the removal of any opportunity to buy into ownership, reduced decision-making ability because of adherence to corporate procedures, extra paperwork, longer approval processes and an increased emphasis on the bottom line.
David Mountford, Chief Executive of BEVA said: "The auditorium is usually full to bursting for our Moral Maze sessions because they bring a broader and more engaging dimension to important topics. The statement Corporatisation of equine practices is inevitable and will benefit vets and their clients is bound to generate some stimulating and possibly heated debate."
This year's BEVA Congress will be held at Liverpool Arena Convention Centre, and anyone who registers before 3rd August will receive significantly reduced booking fees.
For more information, visit: www.beva.org.uk.
The RCVS is advising all practices that it is not currently carrying out a data-gathering exercise and that phone calls prompting the return of a survey, and requesting mobile phone numbers, are not being made on behalf of the College.
The warning comes after several practices have called the College to query 'feedback forms' - supposedly issued in relation to the Practice Standards Scheme or the payment of members' retention fees.
The practices were asked to return forms which they had not received, and also to provide mobile phone numbers, by someone who claimed to work for the 'statutory regulator' or 'the RCVS'. Contact phone numbers left by the caller were either RCVS fax numbers or numbers which looked like RCVS direct dial numbers, but were not.
Lizzie Lockett, Head of Communications, said: "This looks like an exercise to gain mobile phone numbers which is being carried out in the College's name. We are currently investigating who might be making these calls. In the meantime, if a practice receives such a call, it would be helpful if they could take down a name and contact number and let us know."
Ring 020 7202 0725 or email l.lockett@rcvs.org.uk to report any suspicious activity.
Pfizer VPS has launched a 'Pre-Sale Scab Treatment Certificate' so that sheep treated for sheep scab and protected against re-infestation beyond their autumn sale date can be formally certified as such.
A choice of two moxidectin-based treatments are eligible for use, one with 28 days and the other 60 days licensed persistency against the scab mite.
Pfizer VPS vet David Bartram explained that following treatment, the sale date must fall within the persistency window: "The idea is that farmers present their certificate at markets on sale day, then auctioneers announce the scab-protected status during their sales patter. Whether this adds to the sale price will be interesting to find out, but it's sure to be seen as a valuable attribute by buyers who won't need to treat for scab when they arrive home."
Details of the certification process are available from SQPs at animal medicine suppliers. The two eligible treatments are CYDECTIN 1% LA and CYDECTIN 2% LA for sheep.
Dechra Veterinary Products has added to its Veterinary Essentials range of veterinary-licensed post-patent products with the launch of Fiprocat and Fiprodog, a fipronil spot-on solution for the treatment and prevention of on-animal flea infestations in cats and dogs.
Available in packs of 3 or 6 pipettes, Fiprocat and Fiprodog are only distributed through the veterinary channel. Dechra highlights the product's convenient self-standing pipette. which it says makes the process of applying the spot-on easier.
Dechra says it offers a wealth of client support material, and practice promotional support to go with the product.
Fiprocat and Fiprodog can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD).
Rob Simpson at Dechra said: "Fipronil has been used in the treatment and prevention of on-animal flea infestations for many years and is one of the most commonly used treatments in practice. Fiprocat and Fiprodog join R.I.P Fleas Extra to offer a cost effective complete flea solution to tackle both on-animal and environmental flea infestations."
The BSAVA reports the highest ever attendance at Congress this year: 6,178 veterinary surgeons, nurses, practice managers and students, 6% cent higher than in 2011 (the last time the BSAVA hosted its own Congress).
According to the association, a significant number of international delegates attended this year with almost 60 countries represented - notably Scandinavia (186 delegates), Germany (56), the Netherlands (40) and the USA (31).
Other highlights included:
Outgoing BSAVA president Mark Johnston said the event was the highlight of his presidential year: "Last year we showed the world how well the BSAVA can organise a major veterinary congress. But what is pleasing is that the momentum we gained from hosting the World and European meetings has continued into this year.
"We had more delegates in 2013 than in the last purely BSAVA Congress two years ago and to accomplish that in these difficult financial times is a remarkable achievement."
Newly inducted BSAVA president Michael Day (top right) said he was looking forward to extending the international aspect of BSAVA. The Australian-born Professor who has lived in the UK for well over two decades said: "BSAVA has made huge contributions to veterinary practice in the UK, and already has a global reputation for Congress and publications - I believe we have such a wealth of resources and so I am convinced we have so much more to offer the world".
The talks will be free to join live on Zoom, while being simultaneously streamed into the Vet Mums Facebook group.
Following the live stream those on Zoom will be invited to join in a private, unrecorded QnA session.
Liz Barton, co-founder of WellVet and Vet Mums said: “We have spent the last year creating a fab new website for people to access some of the great content WellVet has created over the last few years.
"However, we also noticed a few challenges mentioned with increasing frequency and severity by Vet Mums members.
"It’s fantastic to bring together such great speakers to directly address these issues and provide advice and support to anyone affected.”
For more information, visit www.wellvet.co.uk.
Open to all in the veterinary profession, the event offers up to ten hours of CPD, and covers a range of topics such as orthopaedics, ECC, medicine, wellbeing, and education.
There will also be practical sessions to attend on both days on transfusions, CPR, and physio.
Speakers include:
There's a commercial exhibition, and social events including the Ceilidh at the annual BSAVA PetSavers Gala Dinner on Friday evening.
Prices start at £85 +VAT for a day pass, with early bird rates offered to both BSAVA members and non-members until 27th July.
Additional discounts are available when sending the whole practice team.
https://www.bsavaevents.com/bsavaalba23/en/page/home
The sessions will be delivered by Andrew Kent, clinical director at Blaise and a small animal internal medicine specialist, Lara Dempsey, head of soft tissue surgery, Jacques Ferrerira, head of anaesthesia, Mike Farrell, head of orthopaedic surgery, and neurology clinician, Emma Suiter (pictured).
The talks will cover:
Client communication will also be covered, together with some orthopaedics for those with an interest in that area.
Andy said: “We’re building an incredible team at Blaise and are very excited at the prospect of sharing the specialist knowledge that our clinicians have with our wider veterinary community.
"Treating liver conditions can be incredibly complex and our educational programme presents an unrivalled opportunity to deep dive into this part of an animal’s body and how best to approach it.”
Tickets are available for £48 from https://www.ivcevidensiareferrals.com/Delivering-the-Best, with all profits going to the charity StreetVet.
Blaise Veterinary Referral Hospital in Longbridge is IVC’s first purpose-built pet hospital and will be open to accept referral patients from November 2023.
www.blaise-referrals.com
http://herbertsyard.com
The procedure involves introducing a catheter through the jugular, then using fluoroscopy and transoesophageal echocardiography to guide it from the right atrium through to the left side of the heart to relieve abnormal high pressures in the left atrium.
Willows says it is one of only a few centres across Europe equipped to carry out the procedure and that typically, patients who undergo TSP can be discharged from hospital the day after surgery.
Fabio Sarcinella (pictured right), an RCVS and European specialist in small animal cardiology at Willows, said: “Early clinical evaluation of the TSP procedure in humans over the last few years has shown improved quality of life and reduced clinical signs in patients with heart failure.
“The procedure has also been associated with low-risk and a meaningful drop in left atrial pressure of the affected patients.”
Fabio added: “As well as being minimally invasive, the improvement in heart chamber pressures via TSP often allows for a reduction in the dose of water tablets which are used to control the heart failure signs in the lungs.
"Lowering the dose reduces the risk of side effects related to these drugs such as kidney failure.”
Willows says TSP is most commonly used for left atrial decompression in dogs with heart failure and concurrent renal disease or that have advanced heart failure but continue to have symptoms despite optimal medical treatment.
www.willows.uk.net
'Period prevalence and mortality rates associated with hypocholesterolaemia in dogs and cats: 1,375 cases1' determined the period prevalence of hypocholesterolaemia and the associated mortality rates in dogs and cats at the Veterinary Medical Teaching Hospital, University of California, Davis.
The medical records of cats and dogs presenting to the hospital from 1st September 2011 to 30th August 2016 were retrospectively reviewed to identify all animals that had at least 1 cholesterol measurement; a total of 16,977 dogs and 3,788 cats were identified. Patient signalment and clinical information were collated from the medical records, including the primary disease processes in patients with moderate to severe hypocholesterolaemia. The period prevalence and mortality rate of hypocholesterolaemia were calculated.
The period prevalence of hypocholesterolaemia was 7.0% in dogs and 4.7% in cats. The mortality rate of hypocholesteraemic dogs and cats was 12% in both species, which was significantly higher than that of animals with normal serum cholesterol.
Steven Epstein, corresponding author for the paper, said: 'The odds of death in dogs and cats with hypocholesterolaemia were 3.2 and 2.5 times higher than in those with normocholesterolaemia respectively. Furthermore, there was a significant linear trend towards higher mortality in association with more severe hypocholesterolaemia in both species.
'Disease of the hepatic, gastrointestinal and lymphoreticular systems were most commonly associated with hypocholesterolaemia, and infectious and neoplastic disease were the most commonly associated pathophysiological processes in both species. In dogs with neoplasia, lymphoma was over-represented.'
Nicola Di Girolamo, Editor of JSAP said: 'These findings suggest that low cholesterol levels are associated with mortality in canine and feline patients. It is not clear whether hypocholesterolaemia is simply a marker for disease severity, or if it has active physiological effects contributing to poor outcomes. At this stage, it seems indicated to enhance intensity of diagnostic effort and therapy for affected animals.'
The full article can be found in the November issue of the Journal of Small Animal Practice which is free for BSAVA members. It can also be read online here: https://www.onlinelibrary.wiley.com/doi/10.1111/jsap.13204
The College says this will pave the way for new diagnostic tests for what could be one of the most common causes of pregnancy loss in mares.
The researchers, led by Dr Mandi de Mestre (pictured right), Reader in Reproductive Immunology and Head of the Equine Pregnancy Laboratory at the RVC, collaborated with seven different veterinary practices to gain access to samples from across the UK and Ireland and found that around 20% of the pregnancies lost were aneuploid, which is when a copy of a whole chromosome is either duplicated or lost (similar to Down's).
Charlotte Shilton, RVC PhD, the student who performed the analysis, applied three different genetic approaches to confirm the results.
Work is now underway to identify the underlying cause of these aneuploid pregnancies, with early data from this study suggesting it is most commonly introduced via the egg or sperm. Until now, chromosomal defects such as aneuploidy have only been reported as a rare condition in young horses with developmental disorders.
The researchers say the study explains why the condition is so rare in horses, with most embryos and foetuses possessing this genetic change dying very early in development, as is also observed in human pregnancy. The study highlights the need to reconsider this genetic condition both in pregnancy loss but also for early developmental disorders.
Dr Mandi de Mestre, Reader in Reproductive Immunology at the RVC, said: “Early pregnancy loss remains a very frustrating condition for clinicians to treat as the underlying cause is unknown in around 80% of cases. These findings will allow researchers to develop new diagnostic tests for pregnancy losses, which would offer hope to thousands of owners of breeding mares that suffer this condition.
“A diagnostic test would allow them to make informed decisions on treatment strategies and to advise on whether they should invest in further attempts to breed their mare benefiting both horses and their breeders alike in the future. I would like to thank both the Thoroughbred Breeders Association and our collaborators at Texas A&M University and the participating veterinary surgeons for their support on this project.